GEN Edge最新文献

筛选
英文 中文
Gilead to Acquire CymaBay for $4.3B, Adding to Liver Portfolio 吉利德公司将以 43 亿美元收购 CymaBay,扩充肝脏产品组合
GEN Edge Pub Date : 2024-01-01 DOI: 10.1089/genedge.6.01.027
A. Philippidis
{"title":"Gilead to Acquire CymaBay for $4.3B, Adding to Liver Portfolio","authors":"A. Philippidis","doi":"10.1089/genedge.6.01.027","DOIUrl":"https://doi.org/10.1089/genedge.6.01.027","url":null,"abstract":"","PeriodicalId":140137,"journal":{"name":"GEN Edge","volume":"17 4","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140518516","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
StockWatch: IPO Revival? CG Oncology, ArriVent Raise a Combined $555M 股票观察IPO 复兴?CG Oncology 和 ArriVent 合计融资 5.55 亿美元
GEN Edge Pub Date : 2024-01-01 DOI: 10.1089/genedge.6.01.018
A. Philippidis
{"title":"StockWatch: IPO Revival? CG Oncology, ArriVent Raise a Combined $555M","authors":"A. Philippidis","doi":"10.1089/genedge.6.01.018","DOIUrl":"https://doi.org/10.1089/genedge.6.01.018","url":null,"abstract":"","PeriodicalId":140137,"journal":{"name":"GEN Edge","volume":"41 24","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140518041","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
StockWatch: M&A Talk Fuels Cytokinetics Stock Roller Coaster 股票观察并购话题助推 Cytokinetics 股价过山车
GEN Edge Pub Date : 2024-01-01 DOI: 10.1089/genedge.6.01.011
Alex Philippidis​​​​
{"title":"StockWatch: M&A Talk Fuels Cytokinetics Stock Roller Coaster","authors":"Alex Philippidis​​​​","doi":"10.1089/genedge.6.01.011","DOIUrl":"https://doi.org/10.1089/genedge.6.01.011","url":null,"abstract":"","PeriodicalId":140137,"journal":{"name":"GEN Edge","volume":"19 5","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140517552","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Blood Brothers: Kyverna Reinvents Autologous CAR T Manufacturing from Blood Draw 血液兄弟Kyverna 从抽血中重塑自体 CAR T 制造技术
GEN Edge Pub Date : 2024-01-01 DOI: 10.1089/genedge.6.01.014
Jonathan D. Grinstein
{"title":"Blood Brothers: Kyverna Reinvents Autologous CAR T Manufacturing from Blood Draw","authors":"Jonathan D. Grinstein","doi":"10.1089/genedge.6.01.014","DOIUrl":"https://doi.org/10.1089/genedge.6.01.014","url":null,"abstract":"","PeriodicalId":140137,"journal":{"name":"GEN Edge","volume":"30 7","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140526508","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
StockWatch: Nvidia Shares Leap Again after Reporting Record Revenues 股票观察英伟达公布创纪录收入后股价再次飙升
GEN Edge Pub Date : 2024-01-01 DOI: 10.1089/genedge.6.01.032
A. Philippidis
{"title":"StockWatch: Nvidia Shares Leap Again after Reporting Record Revenues","authors":"A. Philippidis","doi":"10.1089/genedge.6.01.032","DOIUrl":"https://doi.org/10.1089/genedge.6.01.032","url":null,"abstract":"","PeriodicalId":140137,"journal":{"name":"GEN Edge","volume":"162 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140523119","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Light My Fire: COUR Raises $105M Series A to Advance Tolerogenic Nanoparticles for Autoimmunity 点燃我的火焰COUR 获 1.05 亿美元 A 轮融资,推进耐受性纳米粒子治疗自身免疫疾病
GEN Edge Pub Date : 2024-01-01 DOI: 10.1089/genedge.6.01.020
Jonathan D. Grinstein
{"title":"Light My Fire: COUR Raises $105M Series A to Advance Tolerogenic Nanoparticles for Autoimmunity","authors":"Jonathan D. Grinstein","doi":"10.1089/genedge.6.01.020","DOIUrl":"https://doi.org/10.1089/genedge.6.01.020","url":null,"abstract":"","PeriodicalId":140137,"journal":{"name":"GEN Edge","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140524170","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
GSK and Elegen Team Up to Develop DNA-Based Medicines and Vaccines 葛兰素史克与 Elegen 合作开发基于 DNA 的药物和疫苗
GEN Edge Pub Date : 2024-01-01 DOI: 10.1089/genedge.6.01.015
Jonathan D. Grinstein
{"title":"GSK and Elegen Team Up to Develop DNA-Based Medicines and Vaccines","authors":"Jonathan D. Grinstein","doi":"10.1089/genedge.6.01.015","DOIUrl":"https://doi.org/10.1089/genedge.6.01.015","url":null,"abstract":"","PeriodicalId":140137,"journal":{"name":"GEN Edge","volume":"5 11","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140520252","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Form Bio's AI Ensures Gene Therapies Pass Muster, with Ginkgo's Help Form Bio 的人工智能在银杏的帮助下确保基因疗法通过审查
GEN Edge Pub Date : 2024-01-01 DOI: 10.1089/genedge.6.01.034
{"title":"Form Bio's AI Ensures Gene Therapies Pass Muster, with Ginkgo's Help","authors":"","doi":"10.1089/genedge.6.01.034","DOIUrl":"https://doi.org/10.1089/genedge.6.01.034","url":null,"abstract":"","PeriodicalId":140137,"journal":{"name":"GEN Edge","volume":"92 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140522214","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
StockWatch: Challengers Take Aim at Lilly, Novo Nordisk 股票观察挑战者瞄准礼来和诺和诺德
GEN Edge Pub Date : 2024-01-01 DOI: 10.1089/genedge.6.01.036
A. Philippidis
{"title":"StockWatch: Challengers Take Aim at Lilly, Novo Nordisk","authors":"A. Philippidis","doi":"10.1089/genedge.6.01.036","DOIUrl":"https://doi.org/10.1089/genedge.6.01.036","url":null,"abstract":"","PeriodicalId":140137,"journal":{"name":"GEN Edge","volume":"56 17","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140517649","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Drugs, Dollars, and Data: Recursion Eyes Cost Savings from AI Drug Discovery 药物、美元和数据:人工智能药物发现的成本节约
GEN Edge Pub Date : 2024-01-01 DOI: 10.1089/genedge.6.01.016
A. Philippidis
{"title":"Drugs, Dollars, and Data: Recursion Eyes Cost Savings from AI Drug Discovery","authors":"A. Philippidis","doi":"10.1089/genedge.6.01.016","DOIUrl":"https://doi.org/10.1089/genedge.6.01.016","url":null,"abstract":"","PeriodicalId":140137,"journal":{"name":"GEN Edge","volume":"3 4","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140524827","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书